CLX001

Triple Negative Breast Cancer

Discovery Optimisation Pre-clinical Phase 1 Phase 2

CLX001 is held within ValiRx subsidiary company Cytolytix Limited.

Further details available at www.valirx.com/cytolytix

Cytolytix Ltd

Peptide, New Chemical Entity (NCE);

 

Mechanism of Action: Formation of membrane pores;

 

Primary Indication: Triple Negative Breast Cancer;

 

Follow-up Indications: Other hard to treat cancers, including Ovarian Cancer;

 

Licensed from: Kings College London;

 

Published research: "Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer" Chen, C. H., Liu, Y. H., Eskandari, A., Ghimire, J., Lin, L. C., Fang, Z. S., Wimley, W. C., Ulmschneider, J. P., Suntharalingam, K., Hu, C. M. J. & Ulmschneider, M. B., (2022), Advanced Science. 9, 13 2105506. DOIs: https://doi.org/10.1002/advs.202105506

 

Patents: PCT patent family applications: WO 2021/069913; WO 2022/074402